[
  {
    "ts": "2025-07-30T14:00:15+00:00",
    "headline": "Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?",
    "summary": "Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finance.yahoo.com/news/charles-river-laboratories-crl-expected-140015613.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "239cc402-e472-37a4-90b1-efdffc27f4a2",
      "content": {
        "id": "239cc402-e472-37a4-90b1-efdffc27f4a2",
        "contentType": "STORY",
        "title": "Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?",
        "description": "",
        "summary": "Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
        "pubDate": "2025-07-30T14:00:15Z",
        "displayTime": "2025-07-30T14:00:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9",
          "originalWidth": 900,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YtAJ1dNJrNLDESvqOxl.SQ--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9.cf.webp",
              "width": 900,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.P5BxCVxDtGSv3VMOFVgA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-laboratories-crl-expected-140015613.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-laboratories-crl-expected-140015613.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARDT"
            },
            {
              "symbol": "CRL"
            },
            {
              "symbol": "WSFX.BO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T12:20:00+00:00",
    "headline": "Charles River Q2 Earnings Preview: What's in Store for the Stock?",
    "summary": "CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.",
    "url": "https://finance.yahoo.com/news/charles-river-q2-earnings-preview-122000660.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "601d3299-a2f3-3907-afd9-fb4a3d4c53bc",
      "content": {
        "id": "601d3299-a2f3-3907-afd9-fb4a3d4c53bc",
        "contentType": "STORY",
        "title": "Charles River Q2 Earnings Preview: What's in Store for the Stock?",
        "description": "",
        "summary": "CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.",
        "pubDate": "2025-07-30T12:20:00Z",
        "displayTime": "2025-07-30T12:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0b6a08d393cca3baa61f90de397839c4",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rh9k907wwkdNsQxjGuyhOg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0b6a08d393cca3baa61f90de397839c4.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SL.HApql4gLGKFBrPDDxwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0b6a08d393cca3baa61f90de397839c4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-q2-earnings-preview-122000660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/charles-river-q2-earnings-preview-122000660.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CAH"
            },
            {
              "symbol": "COR"
            },
            {
              "symbol": "CRL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-30T09:26:00+00:00",
    "headline": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
    "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
    "url": "https://finance.yahoo.com/news/pharma-formulation-development-outsourcing-forecast-092600050.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e320502a-7634-300b-9532-c21e3096e4e5",
      "content": {
        "id": "e320502a-7634-300b-9532-c21e3096e4e5",
        "contentType": "STORY",
        "title": "Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific",
        "description": "",
        "summary": "The global Formulation Development Outsourcing Market is projected to grow from US$ 33.6 billion in 2024 to US$ 64.74 billion by 2033, at a CAGR of 7.56%. Key growth drivers include rising R&D costs, demand for specialized knowledge, complex regulations, and an expanding pharmaceutical industry. As pharmaceutical and biotech companies increasingly rely on contract development and manufacturing organizations (CDMOs) for integrated, end-to-end services, markets in North America, Europe, and the ra",
        "pubDate": "2025-07-30T09:26:00Z",
        "displayTime": "2025-07-30T09:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/0ceaa2e3467cb322c4be49a4eeac07ad",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Formulation Development Outsourcing Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1kTnbaW3dH2IkKWpPcc31w--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0ceaa2e3467cb322c4be49a4eeac07ad.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NnK_Ouo6pa5N1GE8AyMMrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/0ceaa2e3467cb322c4be49a4eeac07ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-formulation-development-outsourcing-forecast-092600050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-formulation-development-outsourcing-forecast-092600050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRL"
            },
            {
              "symbol": "ERF.PA"
            },
            {
              "symbol": "LH"
            },
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]